Open Access

Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma

  • Authors:
    • Hu Ren
    • Chao‑Rui Wu
    • Saderbieke Aimaiti
    • Cheng‑Feng Wang
  • View Affiliations

  • Published online on: March 29, 2020     https://doi.org/10.3892/ol.2020.11495
  • Pages: 4093-4105
  • Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The survival prediction for patients with resected pancreatic adenocarcinoma by using the Tumor‑Node‑Metastasis (TNM) staging system remains limited. A nomogram is a efficient tool that can be used to predict the outcome of patients with various types of malignancy. The present study aimed to develop and validate a nomogram for patients with resected pancreatic adenocarcinoma. A total of 368 patients (258 in the training set and 110 in the validation set) who underwent pancreatic adenocarcinoma resection at the China National Cancer Center between January 2008 and October 2018 were included in the present study. The nomogram was established according to the results from Cox multivariate analysis, which was validated by discrimination and calibration. The area under the receiver operating characteristic curve (AUC) was determined to assess the accuracy of survival predictions. The results from multivariate analysis in the training set demonstrated that blood transfusion, T‑stage, N‑stage, tumor grade, capsule invasion, carbohydrate antigen 199, neutrophil percentage and adjuvant therapy were independent prognostic factors for overall survival (OS; all P<0.05). Subsequently, a nomogram predicting the 1‑year, 3‑year and 5‑year OS rates, with favorable calibration, was established based on the independent prognostic factors. The concordance indices of the nomogram were higher compared with the TNM staging system in both training and validation sets. Furthermore, a clear risk stratification system based on the nomogram was used to classify patients into the three following groups: Low‑risk group (≤168), moderate‑risk group (168‑255) and high‑risk group (>255). The risk stratification system demonstrated an improved ability in predicting the 1‑year, 3‑year and 5‑year OS rates compared with the TNM system (AUC, 0.758, 0.709 and 0.672 vs. AUC, 0.614, 0.604 and 0.568; all P<0.05). The present study developed and validated a nomogram for patients with resected pancreatic adenocarcinoma by including additional independent prognostic factors, including tumor marker, immune index, surgical information, pathological data and adjuvant therapy. Taken together, the results from the present study indicated an improved performance of the nomogram in predicting the prognosis of patients with resected pancreatic adenocarcinoma compared with the TNM staging system.
View Figures
View References

Related Articles

Journal Cover

June-2020
Volume 19 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ren H, Wu CR, Aimaiti S and Wang CF: Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma. Oncol Lett 19: 4093-4105, 2020.
APA
Ren, H., Wu, C., Aimaiti, S., & Wang, C. (2020). Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma. Oncology Letters, 19, 4093-4105. https://doi.org/10.3892/ol.2020.11495
MLA
Ren, H., Wu, C., Aimaiti, S., Wang, C."Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma". Oncology Letters 19.6 (2020): 4093-4105.
Chicago
Ren, H., Wu, C., Aimaiti, S., Wang, C."Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma". Oncology Letters 19, no. 6 (2020): 4093-4105. https://doi.org/10.3892/ol.2020.11495